Synapse - Sergio Giralt

Results (40)

Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis

Journal Article

Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
Journal of Clinical Oncology (2025)

Fulltext@MSK | Save

Real-world schedule de-escalation of teclistamab in patients with relapsed/refractory multiple myeloma

Meeting Abstract

Tan, C. R. C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Shah, G. L.; Scordo, M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Clinical outcomes of retreatment with daratumumab-based regimens in anti-CD38 refractory multiple myeloma

Meeting Abstract

Tan, C. R. C.; Rueda, C.; Shekarkhand, T.; Derkach, A.; Korde, N.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Minimal residual disease status in multiple myeloma 1 year after autologous hematopoietic cell transplantation and lenalidomide maintenance are associated with long-term overall survival

Journal Article

Pasquini, M. C.; Wallace, P. K.; Logan, B.; Kaur, M.; Tario, J. D. Jr; Howard, A.; Zhang, Y.; Brunstein, C.; Efebera, Y.; Geller, N.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies

Meeting Abstract

Firestone, R.; Shekarkhand, T.; Patel, D.; Tan, C. R. C.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Korde, N.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Health related quality of life (HRQoL) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM) treated with idecabtagene vicleucel (ide-cel) versus standard regimens: Patient-reported outcomes (PROs) from KarMMa-3 phase 3 randomized controlled trial (RCT)

Meeting Abstract

Delforge, M.; Patel, K. K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T.; Arnulf, B.; Cavo, M.; Nooka, A. K.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Plinabulin to shorten neutropenia and improve quality of life peri-autologous hematopoietic cell transplant

Meeting Abstract

Shah, G. L.; Hanley, D.; Datta, A.; Kamrowski, A.; Chung, D. J.; Gupta, G. K.; Hassoun, H.; Hoover, E.; Hultcrantz, M.; Korde, N.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation

Meeting Abstract

Yu, K. H.; Weekes, C. D.; Chen, Y. B. A.; Glazier, J. A.; Glazier, A.; Dahi, P.; Giralt, S.; O'Reilly, E. M.
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Impact of a shared-care model between community and academic centers for facilitating access to allogeneic and autologous stem cell transplantation